GT Biopharma (GTBP) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company developing immuno-oncology products using proprietary TriKE® and Dual Targeting TriKE® fusion protein platforms to harness and enhance natural killer (NK) cell cancer-killing abilities.

• TriKE®s are designed to target multiple tumor antigens in hematologic malignancies and solid tumors, with potential for use as monotherapy or in combination with standard therapies.

• Exclusive rights to the TriKE® platform, with ongoing collaborations and additional intellectual property generation.

Financial performance and metrics

• Raised $9.4 million gross proceeds from the exercise of Greenshoe Rights as of the prospectus date.

• Substantial doubt exists about the ability to continue as a going concern; additional financing is required to fund operations beyond one year from the last annual report.

• As of April 15, 2026, 35,622,375 shares of common stock outstanding, with warrants for up to 57,951,105 additional shares at a weighted average exercise price of $0.62 per share.

Use of proceeds and capital allocation

• No proceeds will be received from the sale of shares by selling stockholders; proceeds from any cash exercise of outstanding Vesting Warrants will be used for working capital and general corporate purposes.